Cardioprotective effects of azilsartan compared with that of telmisartan on an in vivo model of myocardial ischemia-reperfusion injury.

摘要: Azilsartan is found to be more potent than other angiotensin receptor blockers in reducing blood pressure. However, its effect on the heart following myocardial infarction remains established. For first time, we investigated peroxisome proliferator-activated receptor-γ (PPAR-γ) agonistic and cardioprotective properties of azilsartan. Computational modeling studies interactions between azilsartan PPAR-γ revealed as an agonist showed mechanism cardioprotection. Our study compared potential telmisartan that a murine model ischemia-reperfusion injury by comparing their antioxidant, ant apoptotic, anti-inflammatory, mitogen-activated protein kinase (MAPK)-modulating ability, activity. Male Wistar rats were grouped into four receive vehicle (dimethyl sulfoxide [0.05%] 2 ml/kg) (10 mg/kg p.o.), p.o.) or with specific blocker, GW 9662 for 28 days. Ischemia was induced 45 min 29th day followed 60 reperfusion. Telmisartan pretreatment significantly nearly normalized cardiac parameters preserved structural changes. Both drugs inhibited oxidative burst, inflammation, well cell death modulating apoptotic expression along reduction 4',6-diamidino-2-phenylindole/terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells. An increment pro-survival ERK paralleled p38 JNK also MAPK pathway studies, after administration these drugs. Interestingly, aforementioned changes both reversed antagonist, GW9662. upregulated lesser extent latter may preferred hypertensive patients at risk infarction.